Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €29.15 EUR
Change Today -0.61 / -2.05%
Volume 372.1K
ORNBV On Other Exchanges
Symbol
Exchange
Helsinki
Helsinki
OTC US
OTC US
Frankfurt
As of 11:29 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

orion oyj-class b (ORNBV) Snapshot

Open
€29.59
Previous Close
€29.76
Day High
€29.89
Day Low
€29.15
52 Week High
09/30/14 - €31.33
52 Week Low
05/7/14 - €21.61
Market Cap
4.1B
Average Volume 10 Days
442.1K
EPS TTM
€1.59
Shares Outstanding
101.0M
EX-Date
03/25/15
P/E TM
18.3x
Dividend
€1.30
Dividend Yield
4.46%
Current Stock Chart for ORION OYJ-CLASS B (ORNBV)

Related News

No related news articles were found.

orion oyj-class b (ORNBV) Related Businessweek News

No Related Businessweek News Found

orion oyj-class b (ORNBV) Details

Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs. This segment provides proprietary drugs in the areas of central nervous system, oncology and critical care, and pulmonary care; generic prescription drugs, as well as self-care products, such as non-prescription medicines, basic ointments, and vitamins; proprietary and generic veterinary drugs; and APIs for generic and proprietary drugs, as well as offers contract manufacturing services for APIs. This segment also markets and sells veterinary drugs manufactured by other international companies. The Diagnostics segment develops, manufactures, and markets in vitro diagnostic test systems and tests for diagnosing diseases and monitoring treatment efficacy. The company was founded in 1917 and is headquartered in Espoo, Finland.

3,418 Employees
Last Reported Date: 04/29/15
Founded in 1917

orion oyj-class b (ORNBV) Top Compensated Officers

Chairman of the Executive Management Board, C...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

orion oyj-class b (ORNBV) Key Developments

Orion Oyj Announces Consolidated Earnings Results for the First Quarter Ended Mach 31, 2015; Revises Earnings Guidance for the Full Year 2015

Orion Oyj announced consolidated earnings results for the first quarter ended Mach 31, 2015. For the quarter, the company reported net sales of EUR 259.9 million compared with EUR 245.0 million for the same period a year ago. Operating profit was EUR 83.1 million compared with EUR 67.4 million for the same period a year ago. Profit before taxes was EUR 82.7 million compared with EUR 66.5 million for the same period a year ago. Profit for the period was EUR 65.7 million compared with EUR 52.6 million for the same period a year ago. Profit attributable to owners of the parent company was EUR 65.7 million or EUR 0.47 per basic and diluted share compared with EUR 52.6 million or EUR 0.37 per basic and diluted share for the same period a year ago. Total net cash flow from operating activities was EUR 62.9 million compared with EUR 59.1 million for the same period a year ago. Investments in property, plant and equipment was EUR 9.0 million compared with EUR 15.6 million for the same period a year ago. Investments in intangible assets was EUR 1.0 million compared with EUR 1.1 million for the same period a year ago. ROE was 57.4% compared with 46.5% for the same period a year ago. The company revised earnings guidance for the full year 2015. The company upgrades the full-year outlook estimate for 2015. The company estimates that the full-year operating profit will be higher than estimated previously. Net sales will be slightly lower than in 2014. Operating profit is estimated to exceed EUR 230 million compared to EUR 200 million estimated earlier. The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions.

Orion Oyj, Q1 2015 Earnings Call, Apr 29, 2015

Orion Oyj, Q1 2015 Earnings Call, Apr 29, 2015

Orion Corporation Approves Dividend, Payable on April 2, 2015

Orion Corporation at its annual general meeting held March 24, 2015, it approved a dividend of EUR 1.30 per share was confirmed to be paid for 2014. The record date for the dividend payment is 26 March 2015 and the payment date is 2 April 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORNBV:FH €29.15 EUR -0.61

ORNBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.124.10 CHF -2.00
H Lundbeck A/S kr130.50 DKK +0.90
Hospira Inc $87.71 USD -0.02
Shire PLC 5,205 GBp -150.00
View Industry Companies
 

Industry Analysis

ORNBV

Industry Average

Valuation ORNBV Industry Range
Price/Earnings 19.4x
Price/Sales 4.2x
Price/Book 10.8x
Price/Cash Flow 13.9x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORION OYJ-CLASS B, please visit www.orion.fi. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.